Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
June 21, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Condition Afflicts More Than 30...
Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
June 16, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals to Participate in BIO Digital Conference
June 10, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
June 03, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the poster...
Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 26, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it will present...
Tonix Pharmaceuticals to Present at May Investor Summit Virtual Conference
May 12, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
Announced Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800 Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia Expected in Third Quarter 2021 Deep...
Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
April 21, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19
April 19, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, and OyaGen, Inc. (OyaGen), a...
Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth...